WHO WE ARE
As a mid-sized global biopharmaceutical company, Ipsen improves people’s lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.
WHAT WE DO
Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to the communities we serve.
Learn more
Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.
Ipsen News
Find out what’s been going on at Ipsen – discover the latest news, trending stories, and updates on our company.
How Ipsen helps
Ipsen focuses on three key therapeutic areas, leveraging our expertise to help people living with unmet medical needs.
Oncology
With over 35 years of oncology experience, our growing portfolio is focused on difficult-to-treat cancers: pancreatic cancer, follicular lymphoma, epithelioid sarcoma, as well as gastrointestinal and pancreatic neuroendocrine tumors and carcinoid syndrome.
Rare Disease
Our focus is on rare growth disorders and rare liver diseases: Alagille Syndrome, biliary atresia, primary familial intrahepatic cholestasis, primary biliary cholangitis, primary sclerosing cholangitis and fibrodysplasia ossificans progressiva.
Neuroscience
Ipsen brings 30 years of clinical experience to advancing the understanding of neurological conditions such as spasticity and cervical dystonia. We are a global leader in the research, development, manufacturing, and commercialization of neurotoxins.